OAK

Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments

Metadata Downloads
Author(s)
Cho, Sung-Yup; Sung, Chang Ohk; Chae, Jeesoo; Lee, Jieun; Na, Deukchae; Kang, Wonyoung; Kang, Jinjoo; Min, Seoyeon; Lee, Ahra; Kwak, Eunhye; Kim, Jooyoung; Choi, Boram; Kim, Hyunsoo; Chuang, Jeffrey H.; Pak, Hyo-Kyung; Park, Chan-Sik; Park, Sanghui; Ko, Young Hyeh; Lee, Dakeun; Roh, Jin; Cho, Min-Sun; Park, Seongyeol; Ju, Young Seok; Suh, Yun-Suhk; Kong, Seong-Ho; Lee, Hyuk-Joon; Keck, James; Banchereau, Jacques; Liu, Edison T.; Kim, Woo-Ho; Park, Hansoo; Yang, Han-Kwang; Kim, Jong-Il; Lee, Charles
Type
Article
Citation
Blood, v.131, no.17, pp.1931 - 1941
Issued Date
2018-04
Abstract
Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV1-DLBLs) tend to occur in immunocompromised patients, such as the elderly or those undergoing solid organ transplantation. The pathogenesis and genomic characteristics of EBV1-DLBLs are largely unknown because of the limited availability of human samples and lack of experimental animal models. We observed the development of 25 human EBV1-DLBLs during the engraftment of gastric adenocarcinomas into immunodeficient mice. An integrated genomic analysis of the human-derived EBV1-DLBLs revealed enrichment ofmutations in Rho pathway genes, including RHPN2, and Rho pathway transcriptomic activation. Targeting the Rho pathway using a Rho-associated protein kinase (ROCK) inhibitor, fasudil, markedly decreased tumorgrowth inEBV1-DLBL patient-derived xenograft (PDX) models. Thus, alterations in the Rho pathway appear to contribute to EBV-induced lymphomagenesis in immunosuppressed environments.
Publisher
American Society of Hematology
ISSN
0006-4971
DOI
10.1182/blood-2017-07-797209
URI
https://scholar.gist.ac.kr/handle/local/13307
공개 및 라이선스
  • 공개 구분공개
파일 목록
  • 관련 파일이 존재하지 않습니다.

Items in Repository are protected by copyright, with all rights reserved, unless otherwise indicated.